All In Biotech

Drug Trial Radar · NCT06073119

A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis

A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 221 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

221

Actual

Start

Oct 26, 2023

Primary completion

Nov 13, 2024

Study completion Dec 11, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It was designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study details included a screening period (4 weeks and not less than 11 days before Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (4 weeks ± 3 days). The total number of study visits was 7.

Conditions

  • Psoriasis

Interventions

  • SAR441566Drug

    Tablet

  • PlaceboDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a 75% or Greater Psoriasis Area and Severity Index (PASI) Score Reduction From Baseline (PASI75) at Week 12Time frame: Baseline (Day 1) and Week 12

Locations

51 sites in 17 countries. Site status is shown where the registry gives one.

  • Scottsdale Clinical Trials Site Number : 8400025

    Scottsdale, Arizona

  • Dermatology Research Associates- Site Number : 8400019

    Los Angeles, California

  • Daxia Trials Site Number : 8400022

    Boca Raton, Florida

  • Renaissance Research and Medical Group, Inc- Site Number : 8400018

    Cape Coral, Florida

  • Driven Research, LLC- Site Number : 8400012

    Coral Gables, Florida

  • FXM Clinical Research Ft. Lauderdale, LLC Site Number : 8400015

    Fort Lauderdale, Florida

  • Direct Helpers Medical Center Inc- Site Number : 8400023

    Hialeah, Florida

  • FXM Clinical Research Miami, LLC- Site Number : 8400016

    Miami, Florida

  • Center for Clinical Studies, LTD. LLP- Site Number : 8400007

    Houston, Texas

  • Center for Clinical Studies, LTD, LLP- Site Number : 8400013

    Webster, Texas

  • Jordan Valley Dermatology Center- Site Number : 8400027

    South Jordan, Utah

  • Investigational Site Number : 0320003

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    Buenos Aires, Buenos Aires F.D., Argentina

  • Investigational Site Number : 0320002

    CABA, Buenos Aires F.D., Argentina

  • Investigational Site Number : 1000001

    Sofia, Bulgaria

  • Investigational Site Number : 1240006

    London, Ontario, Canada

  • Investigational Site Number : 1240002

    Waterloo, Ontario, Canada

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1560001

    Hangzhou, China

  • Investigational Site Number : 1560002

    Wuxi, China

  • Investigational Site Number : 2030003

    Brno, Czechia

  • Investigational Site Number : 2680002

    Batumi, Georgia

  • Investigational Site Number : 2680001

    Tbilisi, Georgia

  • Investigational Site Number : 2760004

    Blankenfelde-Mahlow, Germany

  • Investigational Site Number : 2760001

    Frankfurt am Main, Germany

  • Investigational Site Number : 2760002

    Witten, Germany

  • Investigational Site Number : 3480003

    Budapest, Hungary

  • Investigational Site Number : 3480002

    Debrecen, Hungary

  • Investigational Site Number : 3920005

    Ichikawa-shi, Japan

  • Investigational Site Number : 3920001

    Yokohama, Japan

  • Investigational Site Number : 3920004

    Kamimashiki Gun, Kumamoto, Japan

  • Investigational Site Number : 3920003

    Sakai-shi, Osaka, Japan

  • Investigational Site Number : 3920006

    tabashi City, Tokyo, Japan

  • Investigational Site Number : 3920002

    Tachikawa-shi, Tokyo, Japan

  • Investigational Site Number : 4800001

    Quatre Bornes, Mauritius

  • Investigational Site Number : 6160001

    Bydgoszcz, Poland

  • Investigational Site Number : 6160002

    Katowice, Poland

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.